Literature DB >> 12202554

Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study.

A Espinel-Ingroff1, A Fothergill, J Peter, M G Rinaldi, T J Walsh.   

Abstract

Standard conditions are not available for evaluating the minimum fungicidal concentrations (MFCs) of antifungal agents. This multicenter collaborative study investigated the reproducibility in three laboratories of itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B MFCs for 15 selected isolates of Aspergillus spp. After MIC determinations for the 15 isolates in each center by the NCCLS M38-A broth microdilution method with four media, standard RPMI 1640 (RPMI), RPMI with 2% dextrose, antibiotic medium 3 (M3), and M3 with 2% dextrose, MFCs were determined for each isolate-medium-drug combination. MFCs were defined as the lowest drug dilutions that yielded <3 colonies (approximately 99 to 99.5% killing activity). The highest reproducibility (96 to 100%) was for amphotericin B MFCs with the four media. Although reproducibility was more variable and medium dependent for the azoles (91 to 98%), agreement was good to excellent for itraconazole, ravuconazole, and voriconazole MFCs with RPMI and M3 (93 to 98%). For posaconazole, the agreement was higher with M3 media (91 to 96%) than with RPMI media (91%). These data extend the refinement of testing guidelines for susceptibility testing of Aspergillus spp. and warrant consideration for introduction into future versions of the M38 document. The role of the MFC under these standardized testing conditions as a predictor of clinical outcome needs to be established in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202554      PMCID: PMC130733          DOI: 10.1128/JCM.40.9.3204-3208.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.

Authors:  A Espinel-Ingroff; M Bartlett; R Bowden; N X Chin; C Cooper; A Fothergill; M R McGinnis; P Menezes; S A Messer; P W Nelson; F C Odds; L Pasarell; J Peter; M A Pfaller; J H Rex; M G Rinaldi; G S Shankland; T J Walsh; I Weitzman
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

2.  Itraconazole resistance in Aspergillus fumigatus.

Authors:  D W Denning; K Venkateswarlu; K L Oakley; M J Anderson; N J Manning; D A Stevens; D W Warnock; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 3.  Therapeutic outcome in invasive aspergillosis.

Authors:  D W Denning
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

4.  In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.

Authors:  K L Oakley; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.

Authors:  K L Oakley; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

6.  Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

Authors:  P Francis; J W Lee; A Hoffman; J Peter; A Francesconi; J Bacher; J Shelhamer; P A Pizzo; T J Walsh
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

7.  Trichosporon beigelii, an emerging pathogen resistant to amphotericin B.

Authors:  T J Walsh; G P Melcher; M G Rinaldi; J Lecciones; D A McGough; P Kelly; J Lee; D Callender; M Rubin; P A Pizzo
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

8.  Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.

Authors:  J Berenguer; N M Ali; M C Allende; J Lee; K Garrett; S Battaglia; S C Piscitelli; M G Rinaldi; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.

Authors:  A Espinel-Ingroff; K Dawson; M Pfaller; E Anaissie; B Breslin; D Dixon; A Fothergill; V Paetznick; J Peter; M Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 10.  In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.

Authors:  A Espinel-Ingroff; K Boyle; D J Sheehan
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

View more
  47 in total

1.  Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay.

Authors:  Bertrand Favre; Bettina Hofbauer; Kwang-Soo Hildering; Neil S Ryder
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

Review 2.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

3.  Activity of deferasirox in Mucorales: influences of species and exogenous iron.

Authors:  Russell E Lewis; Georgios N Pongas; Nathaniel Albert; Ronen Ben-Ami; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

4.  Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole.

Authors:  Georgios Chamilos; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Guillermo Garcia-Effron; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Authors:  Susanne Perkhofer; Cornelia Mrazek; Lukas Hartl; Cornelia Lass-Flörl
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

7.  Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.

Authors:  Joseph Meletiadis; Charalampos Antachopoulos; Theodouli Stergiopoulou; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

8.  Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole.

Authors:  Eric Nulens; Cathrien Eggink; Antonius J M M Rijs; Pieter Wesseling; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.

Authors:  Russell E Lewis; Ronen Ben-Ami; Leyla Best; Nathaniel Albert; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2012-12-13       Impact factor: 5.226

10.  Identification and characterization of a dual-acting antinematodal agent against the pinewood nematode, Bursaphelenchus xylophilus.

Authors:  Wan-Suk Oh; Pan-Young Jeong; Hyoe-Jin Joo; Jeong-Eui Lee; Yil-Seong Moon; Hyang-Mi Cheon; Jung-Ho Kim; Yong-Uk Lee; Yhong-Hee Shim; Young-Ki Paik
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.